Inhibition of Cardiac Ca 2+ Release Channels (RyR2) Determines Efficacy of Class I Antiarrhythmic Drugs in Catecholaminergic Polymorphic Ventricular Tachycardia

Purkinje Cells From RyR2 Mutant Mice Are Highly Arrhythmogenic But Responsive to Targeted Therapy

(2010) Guoxin Kang et al.   CIRCULATION RESEARCH

Power and pitfalls of using transgenic mice to optimize therapy for CPVT: A need for prospective placebo-controlled clinical trials in genetic arrhythmia disorders

(2010) Björn C. Knollmann   HEART RHYTHM

Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice

(2010) Guy Katz et al.   HEART RHYTHM

Incidence and Risk Factors of Arrhythmic Events in Catecholaminergic Polymorphic Ventricular Tachycardia

(2009) Meiso Hayashi et al.   CIRCULATION

Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass

(2009) Fredrick A. Hilliard et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans

(2009) Hiroshi Watanabe et al.   NATURE MEDICINE

Modulation of SR Ca Release by Luminal Ca and Calsequestrin in Cardiac Myocytes: Effects of CASQ2 Mutations Linked to Sudden Cardiac Death

(2008) Dmitry Terentyev et al.   BIOPHYSICAL JOURNAL

Sudden Death in a Young Man with Catecholaminergic Polymorphic Ventricular Tachycardia and Paroxysmal Atrial Fibrillation

(2008) STEPHEN PIZZALE et al.   JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY

Ryanodine receptor and calsequestrin in arrhythmogenesis: What we have learnt from genetic diseases and transgenic mice

(2008) Nian Liu et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Left Cardiac Sympathetic Denervation for Catecholaminergic Polymorphic Ventricular Tachycardia

(2008) Arthur A.M. Wilde et al.   NEW ENGLAND JOURNAL OF MEDICINE